EDIT-202

N/A

Report date: 2023/01/08 14:04:06

Base Information

Drug NameEDIT-202
Drug Alias NameEDIT202
ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy
Mechanisms of ActionImmunologic cytotoxicityNatural killer cell replacements
TargetsNot applicable
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesBluerock Therapeutics LpEditas Medicine Inc
China Registration ClassN/A

Develop Information

Active CompaniesEditas Medicine IncBluerock Therapeutics LpShoreline Biosciences Inc
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A